Despite the need, there are no FDA-approved medications to treat cannabis use disorder. AEF0117 is the first of a new pharmacologic class, type 1 cannabinoid receptor signaling-specific inhibitors ...
Objectives: To evaluate the impact of a physician-led point of care medication delivery system (POCMDS) on adherence to glucose, blood pressure, and cholesterol-lowering medications. Study Design: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results